In a recent announcement, TVA Medical said that it was able to raise US$9,5 million in series B financing. Leading the finance round was S3 Ventures and was joined in by existing investors TriStar Technology Ventures and Sante Ventures.
TVA is based out of Austin, TX and is a medical device company. It is currently developing low invasive therapies specifically for End Stage Renal Disease patients. The main tool used is a catheter based system that would allow doctors to join an artery to a vein called an arterio venous fistula in order to better deliver hemodialytic therapies for patients suffering from kidney failure.
According to the founder of TVA Medical, William Cohen MD, said, "The results to date suggest that durable arterio-venous fistulas can be safely and reproducibly created without surgery. The potential to significantly improve care for renal failure patients while decreasing the cost of dialysis delivery is substantial," Cohen is also the Director of Minimally Invasive Technology at the Texas Heart Institute of the St. Luke's Episcopal Hospital located in Houston, TX.
Join the Conversation